



UK Health
Security
Agency

Routes of transmission of meningococcal infection

A systematic evidence summary

Contents

Main messages.....	3
Purpose.....	4
Methods	4
Evidence	5
Health inequalities.....	7
Limitations.....	7
Evidence gaps	8
Conclusion	8
Acknowledgments.....	8
Disclaimer	9
References.....	9
Annexe A. Protocol	10
Annexe B. Study selection flowchart.....	21
Annexe C. Excluded full texts	23
Annexe D. Data extraction tables.....	35
About the UK Health Security Agency	37

Main messages

1. This systematic evidence summary (search up to 26 March 2026) identified and summarised evidence relating to the most common routes of transmission of meningococcal infection.
2. Three studies were included, of which 2 were case series ([1](#), [2](#)), and one was an outbreak report ([3](#)). One study was conducted in New Zealand ([1](#)), one in the UK ([2](#)), and one in the USA ([3](#)). Transmission events were reported in clusters of 2 to 3 individuals. One study reported on meningococcal serogroup B ([1](#)), one reported on meningococcal serogroup C ([3](#)), and one could not determine the meningococcal serogroup ([2](#)).
3. Two studies (one case series and one outbreak report) reported on presumed sexual transmission of meningococcal infection: one in meningococcal serogroup B ([1](#)), and one with undetermined meningococcal serogroup ([2](#)). One case series reported on presumed transmission through infectious respiratory secretions (meningococcal serogroup C) ([3](#)).
4. No evidence was identified on routes of transmission for meningococcal serogroups A, W, X, or Y, nor for the transmission routes of direct contact or fomites. No evidence was identified in children.
5. Critical appraisal was not performed, which restricts the interpretation of the findings, although limitations of the evidence have been highlighted. The available studies where transmission of meningococcal infection had occurred all only had a small number of transmission events, and so may not be generalisable to wider populations. Included evidence consisted of case series and outbreak reports, which are generally considered lower-quality study designs and more likely to be affected by methodological limitations such as recall bias, incomplete reporting and not adjusting for other factors that may have affected the outcome.
6. In summary, available evidence on the routes of transmission was limited in both quantity and quality. Although some evidence was identified suggesting the possibility of sexual transmission, and one study through infectious respiratory secretions, these were not confirmed and so other transmission routes (such as direct contact) may have contributed. It is not possible from the available evidence to conclude what the most common routes of transmission of meningococcal infection are. No evidence was identified in this systematic evidence summary for direct contact or fomite transmission, but this should not be taken as confirmation that this does not occur.

Purpose

The purpose of this systematic evidence summary was to identify and summarise the available evidence to determine the most common routes of transmission for meningococcal infection, considering all meningococcal serogroups.

The review question was:

1. What are the most common routes of transmission for meningococcal infection in humans?

This systematic evidence summary was commissioned to help inform the UKHSA response to the meningococcal disease outbreak in Kent in March 2026.

Methods

A systematic evidence summary was conducted, following streamlined rapid systematic review methods to accelerate the review process. A literature search was undertaken to look for relevant observational (cohort, cross-sectional or case-control) or descriptive (case series or outbreak reports), published or available as preprints, up to 26 March 2026. Three databases were searched OVID Medline, OVID Embase, and Web of Science Preprint Citation Index.

Studies were included if they reported on confirmed human-to-human transmission of meningococcal infection (any meningococcal serogroup) through the following routes:

- infectious respiratory secretions (droplet or aerosol)
- direct contact
- fomite
- sexual

Studies were not included if they did not report an explicit route of transmission, such as studies that reported on risk factors for carriage or infection, or studies that reported a potential location (such as a bar, or place of education) of transmission without an explicit route. Studies that reported 'close contact' without an explicit route of transmission were also excluded.

A protocol was produced before the literature search was conducted, including the review question, the eligibility criteria, and all other methods. Full details of the methodology are provided in the protocol in [Annexe A](#).

There were no deviations from the protocol, but 4 clarifications were made:

- the review question was amended from 'meningococcal disease' to meningococcal infection'

- outbreak reports were included regardless of whether they had been peer-reviewed
- the transmission routes 'droplet', 'respiratory', and 'airborne or aerosol' were changed to 'infectious respiratory secretions (droplet or aerosol)'
- exposure was altered from 'meningococcal disease' to 'meningococcal infection (at least one case confirmed with meningococcal disease)'

Screening of title and abstracts was undertaken in duplicate by 2 reviewers for 10% of records, with the remainder completed by one reviewer. Screening on full texts was undertaken by one reviewer and excluded studies were checked by a second reviewer.

Data extraction was performed by one reviewer and checked by a second.

Evidence

In total, 4,352 studies were screened at title and abstract and 139 studies were screened at full text stage. Of these, 3 studies met the inclusion criteria. A PRISMA diagram showing the flow of studies through the systematic evidence summary is shown in [Annexe B](#), and studies excluded on full text screening are available with the reasons why in [Annexe C](#). Study characteristics are available in [Annexe D](#).

Of the 3 included studies, 2 were case series ([1](#), [2](#)) and one was an outbreak report ([3](#)). One study was conducted in New Zealand ([1](#)), one in the UK ([2](#)), and one in the USA ([3](#)). Transmission events were limited to clusters of 2 to 3 individuals.

Meningococcal serogroup B

One study was identified that reported on the route of transmission of meningococcal serogroup B ([1](#)). Findings from this study are presented in [Table D.1](#).

Mitchell and others reported a series of 5 cases where *Neisseria meningitidis* (*N. meningitidis*) was isolated from genital swabs in people attending a sexual health clinic in New Zealand in 2007 ([1](#)). There was suspected transmission between 2 of the 5 cases. One case, a 20 year old woman presenting with intermenstrual and post coital bleeding, had throat, vaginal, cervical and urethral swabs taken. *N. meningitidis* was identified at all sites, and tests for all other sexually transmitted infections were negative. She reported unprotected vaginal and oral sex with a regular partner, a 23 year old man. A throat swab was subsequently taken from him, which was positive for meningococcal serogroup B. He did not have any symptoms, but both were treated with ciprofloxacin. A second throat swab taken 4 days later was negative for meningococcal serogroup B. It is unclear whether the woman or man was the index case, and transmission route was presumed as sexual, infection may have been transmitted through another route (such as contact with infectious respiratory secretions). There was no information on the likely route of transmission for the other cases, and no reported connection between the other cases.

Meningococcal serogroup C

One study (an outbreak report) reported on routes of transmission for meningococcal serogroup C (3). Evidence from this study is summarised in [Table D.2](#).

The outbreak report, by Materna and others, reported transmission events of meningococcal serogroup C, after occupational contact with a person with confirmed meningococcal disease in the USA in 2009 (3). The index case, a 36 year old man, was found unconscious in his home with a partially obstructed airway and vomit and faeces on his clothes and body. Two secondary cases were subsequently reported:

1. A 30 year old man who was a police officer began experiencing symptoms 2 days after attending the scene. After hospitalisation, blood and cerebrospinal fluid samples were positive for *N. meningitidis*. He adjusted the body and head of the index case to assist with their breathing and then left the room. He reported hearing hacking and gurgling from the patient but reported no droplets on his skin nor contact with respiratory secretions. He wore gloves while attending the patient, but did not wear a mask.
2. A 47 year old man who was a respiratory therapist assisted with suction of the airway of the index case and placement of a tube into their airway. He reported symptoms 5 days after coming into contact with the index case, and blood and cerebrospinal fluid samples were positive for *N. meningitidis*. He wore gloves while attending the patient, but did not wear a mask.

The authors suggest that in both secondary cases, unprotected exposure to infectious respiratory secretions (defined by the authors as respiratory aerosols or secretions) may have resulted in the transmission of meningococcal infection.

Meningococcal serogroup not determined

One case series was identified that reported transmission of meningococcal infection where meningococcal serogroup could not be determined (2). This paper is summarised in [Table D.3](#).

One case, a 26 year old man, presented with urethral discharge and dysuria. He reported sexual intercourse with 2 women (ages not reported), both of whom subsequently attended the clinic on his advice. Urethral swabs were taken from the man, while throat, urethral, cervical and rectal swabs were taken from the 2 women. *N. meningitidis* was isolated from the urethral swab of the man, the cervical swab of one woman and the throat swab of the other woman. Sexual transmission was presumed as the likely route by the authors, who suggested that the man acquired meningococcal infection from sexual contact with one woman via oral-genital exposure and then transmitted meningococcal infection to the second woman through vaginal sexual intercourse. However, meningococcal infection may have been transmitted through another route (such as contact with infectious respiratory secretions) due to close proximity during sexual intercourse.

Health inequalities

No evidence was identified for any of the subgroups listed in the protocol for whom the outcome of meningococcal disease may differ, such as those in school or university, those who reside in high-risk settings such as boarding school, children's homes or places of detention, or those under 18 years of age who are unvaccinated. No evidence was identified on ethnicity or deprivation.

Limitations

This systematic evidence summary used streamlined systematic methods to accelerate the rapid evidence summary process. Sources of evidence searched included databases of peer-reviewed and preprint research, but an extensive search of other sources was not conducted and most article screening was completed without duplication, so it is possible relevant evidence may have been missed.

Critical appraisal was not performed due to the rapid completion of this work. This restricts the interpretation of the findings, but the main limitations have been highlighted. Included studies were case series and outbreak reports. Evidence from these sources is generally considered of lower quality, and there are important methodological considerations (including incomplete reporting of linked cases, and uncertainties around exposures and potential transmission events) that limit the ability to interpret the evidence identified. There was only available evidence for 2 to 3 people per study where likely transmission route could be identified. This is too few to be able to make any conclusions on common transmission routes. Two of the 3 included studies reported sexual transmission, however, it is possible that other transmission routes could have also contributed to transmission. The fact that 2 out of 3 studies highlighted sexual transmission could be an overrepresentation of what occurs, as case series or outbreak reports tend to present unexpected events. It is also unlikely that these studies identified all cases related to the outbreaks – asymptomatic or mild cases may have been missed.

The available evidence on routes of transmission of meningococcal infection was very limited. It can be difficult to determine the route of transmission, for example while sexual transmission may be presumed, there is the potential that other routes of transmission (such as respiratory or direct contact) may have contributed. In general, the route of transmission of meningococcal infection was not well documented. This may be due to limited transmissibility, the unpredictability of transmission events, or that asymptomatic carriage of *N. meningitidis* in the population is common, making it difficult to identify a single source of transmission. In addition, there may have been rapid deployment of antibiotics to identified close contacts of cases which would make sustained transmission unlikely.

This evidence summary sought to identify evidence on the route of transmission of meningococcal infection and so did not include studies that reported on risk factors for carriage

or infection, nor studies that reported a potential location of transmission without an explicit route. Studies that reported 'close contact' without an explicit route of transmission were also excluded. Evidence from such studies may be able to provide additional information to inform most common transmission route.

Evidence gaps

This evidence summary identified available evidence on the most common routes of transmission of meningococcal infection. Evidence was limited for meningococcal serogroups B and C. No evidence was identified for meningococcal serogroups A, W, X, or Y.

Although evidence on direct contact, fomite, infectious respiratory secretions (droplet or aerosol), or sexual transmission was searched for, the only evidence identified was for sexual and infectious respiratory secretions (droplet or aerosol). No evidence was identified that specified transmission through direct contact or fomite transmission.

No evidence was identified in children and only one study included a transmission event between young adults ([1](#)).

Conclusion

This systematic evidence summary identified 3 studies that reported on routes of transmission of meningococcal infection, where confirmed transmission events had occurred; 2 studies reported on presumed sexual transmission, and one reported on suspected transmission through infectious respiratory secretions. However, it can be difficult to determine route of transmission, as for example while sexual transmission was presumed in 2 of the included studies, there is the potential that other routes of transmission (such as infectious respiratory secretions or direct contact) may have contributed.

Critical appraisal was not performed, which restricts the interpretation of the findings. However, important limitations have been highlighted in this report, most notably the very small numbers of people in whom a possible transmission route was described. The route of transmission of meningococcal infection was not well documented, and evidence was limited to outbreak reports and case series. From the identified evidence, it is not possible to conclude what the most common routes of transmission of meningococcal infection are.

Acknowledgments

We would like to thank colleagues within the All Hazards Public Health Response division who either reviewed or input into aspects of the evidence summary.

Disclaimer

UKHSA's rapid reviews and evidence summaries aim to provide the best available evidence to decision makers in a timely and accessible way, based on published peer-reviewed scientific papers, and papers on preprint servers. Note that the reviews:

- use accelerated methods and may not be representative of the whole body of evidence publicly available
- have undergone an internal independent peer review but not an external peer review
- are only valid as of the date stated on the review

In the event that this evidence summary is shared externally, note additionally, to the greatest extent possible under any applicable law, that UKHSA accepts no liability for any claim, loss or damage arising out of, or connected with the use of, this review by the recipient or any third party including that arising or resulting from any reliance placed on, or any conclusions drawn from, the review.

References

1. Mitchell L and others. '[An unexpected increase in *Neisseria meningitidis* genital isolates among sexual health clinic attendees, Hamilton, New Zealand](#)' Sexually Transmitted Diseases 2008: volume 35, issue 5, pages 469 to 471
2. Talbot MD and others. '[Presumed sexual transmission of meningococci](#)' Journal of Infection 1981: volume 3, issue 3, pages 273 to 276
3. Materna. '[Occupational transmission of *Neisseria meningitidis* --- California, 2009](#)' MMWR - Morbidity and Mortality Weekly Report 2010: volume 59, issue 45, pages 1,480 to 1,483

Annexe A. Protocol

Review question

The review question is:

1. What are the most common routes of transmission for meningococcal infection in humans?

A search for primary evidence to answer this review question will be conducted up to 26 March 2026.

Eligibility criteria

Table A.1 Inclusion and exclusion criteria

	Included	Excluded
Population	Humans (any age): • children (aged up to and including 17 years) • 0 to 4 years, 5 to 11 years, 12 to 17 years • adults (18 years and over) • young adults 18 to 25 years	Animals
Settings	Any	
Intervention or exposure	Meningococcal infection (at least one case confirmed with meningococcal disease)	
Outcomes	Confirmed human-to-human transmission through the following routes: • infectious respiratory secretions (droplet or aerosol) • direct contact • fomite • sexual	Animal-to-human transmission
Language	English	Any other language
Date of publication	Up to 26 March 2026	
Study design	Observational studies: case-control, cross-sectional, and cohort studies	Experimental studies (randomised-controlled trials, quasi-experimental studies, cross-over

	Included	Excluded
	Descriptive studies including case series or outbreak reports	designs, before-and-after studies) Systematic or narrative reviews Modelling studies Case reports
Publication type	Peer-reviewed published research Preprints	Editorials Letters News articles Grey literature Conference abstracts

Identification of studies

The following databases will be searched for studies published up to 26 March 2026: OVID Medline, OVID Embase, and Web of Science Preprint Citation Index. The [search strategy](#) is presented below.

Screening

Title and abstract screening will be undertaken in duplicate by 2 reviewers for at least 10% of the eligible studies, with the remainder completed by one reviewer. Disagreement will be resolved by discussion or with involvement of a third reviewer where necessary.

Screening on full text will be undertaken by one reviewer and checked by a second.

Data extraction

Summary information for each study will be extracted and reported in tabular form. Information to be extracted will include country, study period, study design, setting, participants, results, and any relevant contextual data. This will be undertaken by one reviewer and checked by a second.

Risk of bias assessment

Risk of bias of included studies will not be assessed in this systematic evidence summary due to time constraints, but important limitations of the evidence will be highlighted.

Synthesis

Where studies are similar enough to combine and present data in a consistent format, a narrative synthesis will be produced to interpret the findings. The number of studies, the number of participants in each study, effect size and variance and a summary of study limitations across studies reporting each outcome will be summarised and presented. Alternatively, if studies present methodological differences that would make synthesis inappropriate, a narrative summary of each study will be provided.

Results will be presented in the following sub-groups: meningitis B, all other serogroups.

Health inequalities

Variations across the following populations and subgroups for whom the outcome of meningococcal disease may differ will be considered, where evidence is available:

- those in early years and educational settings, (including nurseries, schools, further education colleges, sixth form, SEN schools, universities), considering difference by year group (both school and university)
- those who take part in behaviours that may increase transmission rates (vaping, kissing, sharing social spaces, social networks)
- children (aged under 18 years) who remain unvaccinated (under one year of age who are eligible for MenB vaccination but did not receive it, children who are unvaccinated for any other reason)
- those who reside in potentially high-risk settings for disease transmission including in education (boarding schools, university halls), and other residential settings such as children's homes, adult social care settings, prisons and places of detention, asylum and migrant settings, homeless settings
- those in different ethnic groups
- by deprivation
- those who work in or who have visited higher risk congregate workplaces or entertainment venues (warehouses, factories, nightclubs, sex on premises venues, music venues, bars, student parties, religious venues, choir practices, other crowded indoor social settings)

Search strategy

Ovid MEDLINE(R) ALL (1 January 1946 to 25 March 2026)

1. exp Meningococcal Infections/ (12,165)
2. exp Meningitis, Meningococcal/ (5,802)
3. Meningitis, Bacterial/ (8,189)
4. (meningococc* adj5 (infect* or disease* or strain* or meningit*)).tw,kf. (9,324)
5. invasive meningococc*.tw,kf. (1,696)

6. meningococcosis.tw,kf. (14)
7. (meningit* and (septic?em* or sepsis or bacter?em*)).tw,kf. (9,249)
8. (meningococc* and (septic?em* or sepsis or bacter?em*)).tw,kf. (1,979)
9. exp Neisseria meningitidis/ (10,640)
10. neisseria mening*.tw,kf. (9,638)
11. "N. meningitidis".tw,kf. (3,192)
12. (meningococc* adj2 A).tw,kf. (2,165)
13. (meningit* adj3 A).tw,kf. (11,536)
14. (meningococc* adj2 B).tw,kf. (1,726)
15. (meningit* adj3 B).tw,kf. (2,266)
16. (meningococc* adj2 C).tw,kf. (1,390)
17. (meningit* adj3 C).tw,kf. (989)
18. (meningococc* adj2 W).tw,kf. (138)
19. (meningit* adj3 W).tw,kf. (144)
20. (meningococc* adj2 X).tw,kf. (34)
21. (meningit* adj3 X).tw,kf. (77)
22. (meningococc* adj2 Y).tw,kf. (131)
23. (meningit* adj3 Y).tw,kf. (185)
24. exp Sepsis/ and Meningitis/ (1,311)
25. serogroup* A.tw,kf. (1,633)
26. serogroup* B.tw,kf. (2,466)
27. serogroup* C.tw,kf. (1,482)
28. serogroup* W-135.tw,kf. (68)
29. serogroup* X.tw,kf. (118)
30. serogroup* Y.tw,kf. (297)
31. MenA.tw,kf. (2,007)
32. MenB.tw,kf. (721)
33. MenC.tw,kf. (455)
34. MenW.tw,kf. (140)
35. MenX.tw,kf. (72)
36. MenY.tw,kf. (108)
37. or/1-36 (46,427)
38. exp Disease Transmission, Infectious/ (87,295)
39. (transmi* adj5 (route* or mode or modes or path or paths or pathway* or method* or way or ways or how or direct* or indirect* or primary or secondary or pattern* or vehicle* or window*)).tw,kf. (70,902)
40. transmi*.ti. (122,313)
41. "human to human".tw,kf. (7,811)
42. "person to person".tw,kf. (4,684)
43. transmi* between human*.tw,kf. (457)
44. transmi* between people.tw,kf. (56)
45. ((direct* or indirect* or close or transmi* or physical* or regular* or frequent* or prolonged or infect*) adj3 contact*).tw,kf. (64,352)
46. interhuman.tw,kf. (240)

47. "inter human".tw,kf. (154)
48. (inter-person* or interperson*).tw,kf. (64,732)
49. (between adj2 (person* or people or population*)).tw,kf. (56,532)
50. (within adj2 population*).tw,kf. (34,109)
51. ((communit* or disease* or infection* or population* or human* or people* or group*) adj3 spread*).tw,kf. (41,835)
52. ((communit* or disease* or infection* or population* or human* or people* or group*) adj3 contagio*).tw,kf. (7,636)
53. "skin to skin".tw,kf. (8,974)
54. "mouth to mouth".tw,kf. (738)
55. "mouth to skin".tw,kf. (172)
56. "hand to mouth".tw,kf. (1,371)
57. "face to face".tw,kf. (51,955)
58. touch*.tw,kf. (49,442)
59. (horizontal* adj2 transmit*).tw,kf. (773)
60. exp Inhalation Exposure/ (11,075)
61. exp Inhalation/ (6,088)
62. exp Exhalation/ (5,416)
63. exp Respiration/ (126,127)
64. exp "Aerosolized Particles and Droplets"/ (45)
65. exp "Respiratory Aerosols and Droplets"/ (692)
66. (respiratory adj3 transmi*).tw,kf. (2,219)
67. exp Aerosols/ (38,592)
68. exp Air Microbiology/ (8,988)
69. aerosol*.tw,kf. (63,965)
70. droplet*.tw,kf. (77,992)
71. airborne.tw,kf. (30,844)
72. air borne.tw,kf. (1,169)
73. air* particle*.tw,kf. (3,500)
74. respiratory particle*.tw,kf. (134)
75. expiratory particle*.tw,kf. (8)
76. exhal*.tw,kf. (19,678)
77. inhal*.tw,kf. (141,838)
78. air sampl*.tw,kf. (8,876)
79. (respiratory adj (route* or mode* or path* or method* or transmi* or spread*)).tw,kf. (10,695)
80. (expiratory adj (route* or mode* or path* or method* or transmi* or spread*)).tw,kf. (24)
81. (airway* adj (route* or mode* or path* or method* or transmi* or spread*)).tw,kf. (1,941)
82. (air way* adj (route* or mode* or path* or method* or transmi* or spread*)).tw,kf. (0)
83. (breath* adj (route* or mode* or path* or method* or transmi* or spread*)).tw,kf. (1,836)
84. ((air flow* or airflow* or aerodynamic* or air condition* or cough* or sneez* or breath* or sing or singing or shout* or (air adj2 circulat*) or (air adj2 recirculation) or (air adj2 re-circulation)) and (transmission* or transmit* or distanc* or dispers*)).tw,kf. (13,243)
85. ((ventilation or ventilated) and (transmission* or distanc* or dispers*)).tw,kf. (5,564)

86. bioaerosol*.tw,kf. (2,782)
87. exp Fomites/ (705)
88. (fomite* or fomes).tw,kf. (1,983)
89. ((contaminat* or transmi*) adj3 (surface* or environment* or touch* or object* or equipment or food or drink*)).tw,kf. (47,522)
90. ((Virus or viral*) adj5 (touch* or surface*)).tw,kf. (11,431)
91. (bacteri* adj5 (touch* or surface*)).tw,kf. (23,194)
92. Body Fluids/ (36,106)
93. exp Bodily Secretions/ (299,981)
94. ((body or bodily) adj fluid*).tw,kf. (32,289)
95. ((body or bodily) adj secretion*).tw,kf. (416)
96. exp Saliva/ (50,687)
97. exp Respiratory Mucosa/ (40,746)
98. exp Nasal Mucosa/ (29,635)
99. saliva*.tw,kf. (136,430)
100. spit*.tw,kf. (86,757)
101. (muc\$us or mucosa).tw,kf. (202,882)
102. (phlegm or sputum).tw,kf. (43,647)
103. ((nostril* or nasal) adj3 (discharge* or secretion*)).tw,kf. (6,614)
104. (kiss or kissing).tw,kf. (5,697)
105. ((mouth or tongue or lip*) adj3 contact*).tw,kf. (1,630)
106. ((shared or sharing) adj3 (utensil* or fork* or spoon* or knife or knives or cup* or mug* or glass* or tumbler* or food or drink*)).tw,kf. (1,123)
107. exp Sexual Behavior/ (134,278)
108. (sexual* adj3 (transmi* or spread* or contact* or disease* or infect*)).tw,kf. (56,584)
109. exp Vaginal Discharge/ (1,939)
110. (Vagina* adj3 (fluid* or secret* or discharge* or transmi* or spread* or disease* or contact*)).tw,kf. (10,492)
111. ((penile or penis) adj3 (fluid* or secret* or discharge* or ejaculat* or transmi* or spread* or disease* or contact*)).tw,kf. (1,443)
112. (ejaculat* adj3 fluid*).tw,kf. (170)
113. seminal fluid*.tw,kf. (3,269)
114. exp Semen/ (26,662)
115. semen.tw,kf. (41,338)
116. or/38-115 (2,046,227)
117. 37 and 116 (3,137)
118. limit 117 to (comment or editorial or letter or news or newspaper article) (86)
119. 117 not 118 (3,051)

Embase (1 January 1974 to 25 March 2026)

1. exp meningococcosis/ (15,157)
2. exp epidemic meningitis/ (3,785)
3. *bacterial meningitis/ (11,468)
4. (meningococc* adj5 (infect* or disease* or strain* or meningit*)).tw,kf. (10,774)
5. invasive meningococc*.tw,kf. (2,026)
6. meningococcosis.tw,kf. (10)
7. (meningit* and (septic?em* or sepsis or bacter?em*)).tw,kf. (12,860)
8. (meningococc* and (septic?em* or sepsis or bacter?em*)).tw,kf. (2,532)
9. exp Neisseria meningitidis/ (17,739)
10. neisseria mening*.tw,kf. (11,186)
11. "N. meningitidis".tw,kf. (3,726)
12. (meningococc* adj2 A).tw,kf. (2,701)
13. (meningit* adj3 A).tw,kf. (14,250)
14. (meningococc* adj2 B).tw,kf. (2,176)
15. (meningit* adj3 B).tw,kf. (2,669)
16. (meningococc* adj2 C).tw,kf. (1,680)
17. (meningit* adj3 C).tw,kf. (1,249)
18. (meningococc* adj2 W).tw,kf. (166)
19. (meningit* adj3 W).tw,kf. (174)
20. (meningococc* adj2 X).tw,kf. (41)
21. (meningit* adj3 X).tw,kf. (96)
22. (meningococc* adj2 Y).tw,kf. (160)
23. (meningit* adj3 Y).tw,kf. (207)
24. exp sepsis/ and meningitis/ (10,149)
25. serogroup* A.tw,kf. (1,926)
26. serogroup* B.tw,kf. (2,842)
27. serogroup* C.tw,kf. (1,687)
28. serogroup* W-135.tw,kf. (82)
29. serogroup* X.tw,kf. (140)
30. serogroup* Y.tw,kf. (348)
31. MenA.tw,kf. (2,744)
32. MenB.tw,kf. (917)
33. MenC.tw,kf. (574)
34. MenW.tw,kf. (150)
35. MenX.tw,kf. (87)
36. MenY.tw,kf. (127)
37. or/1-36 (65,865)
38. exp *disease transmission/ (46,763)
39. (transmi* adj5 (route* or mode or modes or path or paths or pathway* or method* or way or ways or how or direct* or indirect* or primary or secondary or pattern* or vehicle* or window*)).tw,kf. (86,293)
40. transmi*.ti. (129,789)

41. "human to human".tw,kf. (9,481)
42. "person to person".tw,kf. (6,031)
43. transmi* between human*.tw,kf. (520)
44. transmi* between people.tw,kf. (75)
45. ((direct* or indirect* or close or transmi* or physical* or regular* or frequent* or prolonged or infect*) adj3 contact*).tw,kf. (80,491)
46. interhuman.tw,kf. (297)
47. "inter human".tw,kf. (212)
48. (inter-person* or interperson*).tw,kf. (77,832)
49. (between adj2 (person* or people or population*)).tw,kf. (69,923)
50. (within adj2 population*).tw,kf. (42,482)
51. ((communit* or disease* or infection* or population* or human* or people* or group*) adj3 spread*).tw,kf. (49,437)
52. ((communit* or disease* or infection* or population* or human* or people* or group*) adj3 contagio*).tw,kf. (8,818)
53. "skin to skin".tw,kf. (13,556)
54. "mouth to mouth".tw,kf. (915)
55. "mouth to skin".tw,kf. (338)
56. "hand to mouth".tw,kf. (1,741)
57. "face to face".tw,kf. (73,146)
58. touch*.tw,kf. (68,298)
59. (horizontal* adj2 transmit*).tw,kf. (829)
60. exp inhalational exposure/ (955)
61. exp inhalation/ (38,007)
62. exp exhalation/ (36,231)
63. exp *breathing/ (69,177)
64. exp "aerosolized particles and droplets"/ (322)
65. exp "infectious droplets and aerosols"/ (148)
66. exp "respiratory droplets and aerosols"/ (853)
67. (respiratory adj3 transmi*).tw,kf. (2,580)
68. exp aerosol/ (74,283)
69. air microbiolog*.tw,kf. (65)
70. airborne.tw,kf. (38,314)
71. air borne.tw,kf. (1,237)
72. air* particle*.tw,kf. (4,514)
73. droplet*.tw,kf. (90,252)
74. respiratory particle*.tw,kf. (150)
75. expiratory particle*.tw,kf. (8)
76. exhal*.tw,kf. (31,931)
77. inhal*.tw,kf. (208,083)
78. air sampl*.tw,kf. (11,925)
79. (respiratory adj (route* or mode* or path* or method* or transmi* or spread*)).tw,kf. (14,062)
80. (expiratory adj (route* or mode* or path* or method* or transmi* or spread*)).tw,kf. (26)

81. (air way* adj (route* or mode* or path* or method* or transmi* or spread*)).tw,kf. (0)
82. (breath* adj (route* or mode* or path* or method* or transmi* or spread*)).tw,kf. (2,700)
83. ((air flow* or airflow* or aerodynamic* or air condition* or cough* or sneez* or breath* or sing or singing or shout* or (air adj2 circulat*) or (air adj2 recirculation) or (air adj2 re-circulation)) and (transmission* or transmit* or distanc* or dispers*)).tw,kf. (20,596)
84. ((ventilation or ventilated) and (transmission* or distanc* or dispers*)).tw,kf. (8412)
85. bioaerosol*.tw,kf. (3,824)
86. exp fomite/ (1029)
87. (fomite* or fomes).tw,kf. (2,243)
88. ((contaminat* or transmi*) adj3 (surface* or environment* or touch* or object* or equipment or food or drink*)).tw,kf. (54,839)
89. ((Virus or viral*) adj5 (touch* or surface*)).tw,kf. (13,052)
90. body fluid/ (29,951)
91. exp *bodily secretions/ (162,623)
92. ((body or bodily) adj fluid*).tw,kf. (37,097)
93. ((body or bodily) adj secretion*).tw,kf. (466)
94. exp saliva/ (52,194)
95. exp respiratory mucosa/ (37,801)
96. exp nose mucosa/ (20,034)
97. saliva*.tw,kf. (166,418)
98. spit*.tw,kf. (119,375)
99. (muc\$us or mucosa).tw,kf. (276,800)
100. (phlegm or sputum).tw,kf. (72,691)
101. ((nostril* or nasal) adj3 (discharge* or secretion*)).tw,kf. (8,721)
102. (kiss or kissing).tw,kf. (8,494)
103. ((mouth or tongue or lip*) adj3 contact*).tw,kf. (1,925)
104. ((shared or sharing) adj3 (utensil* or fork* or spoon* or knife or knives or cup* or mug* or glass* or tumbler* or food or drink*)).tw,kf. (1,292)
105. exp sexual behavior/ (285,648)
106. (sexual* adj3 (transmi* or spread* or contact* or disease* or infect*)).tw,kf. (73,298)
107. vaginal secretion/ (3,450)
108. (Vagina* adj3 (fluid* or secret* or discharge* or transmi* or spread* or disease* or contact*)).tw,kf. (14,325)
109. ((penile or penis) adj3 (fluid* or secret* or discharge* or ejaculat* or transmi* or spread* or disease* or contact*)).tw,kf. (2,078)
110. (ejaculat* adj3 fluid*).tw,kf. (185)
111. seminal fluid*.tw,kf. (4,042)
112. exp sperm/ (93,959)
113. semen.tw,kf. (54,404)
114. or/38-113 (2,400,489)
115. 37 and 114 (4,175)
116. limit 115 to (conference abstract or conference paper or "conference review" or editorial or letter) (869)
117. 115 not 116 (3,306)

Web of Science Preprint Citation Index (1990 to current)

Date of search: 26 March 2026

TS=((meningococc* NEAR/4 (infect* or disease* or strain* or meningit*))) OR TS=("invasive meningococc*") OR TS=(meningococcosis) OR TS=((meningit* and (septicsem* or sepsis or bactersem*))) OR TS=((meningococc* and (septicsem* or sepsis or bactersem*))) OR TS=("neisseria mening*") OR TS=("N. meningitidis") OR TS=((meningococc* NEAR/1 A)) OR TS=((meningit* NEAR/2 A)) OR TS=((meningococc* NEAR/1 B)) OR TS=((meningit* NEAR/2 B)) OR TS=((meningococc* NEAR/1 C)) OR TS=((meningit* NEAR/2 C)) OR TS=((meningococc* NEAR/1 W)) OR TS=((meningit* NEAR/2 W)) OR TS=((meningococc* NEAR/1 X)) OR TS=((meningit* NEAR/2 X)) OR TS=((meningococc* NEAR/1 Y)) OR TS=((meningit* NEAR/2 Y)) OR TS=("serogroup* A") OR TS=("serogroup* B") OR TS=("serogroup* C") OR TS=("serogroup* W-135") OR TS=("serogroup* X") OR TS=("serogroup* Y") OR TS=(MenA) OR TS=(MenB) OR TS=(MenC) OR TS=(MenW) OR TS=(MenX) OR TS=(MenY)

AND


TS=((transmi* NEAR/4 (route* or mode or modes or path or paths or pathway* or method* or way or ways or how or direct* or indirect* or primary or secondary or pattern* or vehicle* or window*))) OR TI=(transmi*) OR TS=("human to human") OR TS=("person to person") OR TS=("transmi* between human*") OR TS=("transmi* between people") OR TS=((direct* or indirect* or close or transmi* or physical* or regular* or frequent* or prolonged or infect* NEAR/2 contact*)) OR TS=(interhuman) OR TS=("inter human") OR TS=(inter-person* OR interperson*) OR TS=((between NEAR/1 (person* or people or population*))) OR TS=((within NEAR/1 population*)) OR TS=((communit* or disease* or infection* or population* or human* or people* or group*) NEAR/2 spread*)) OR TS=((communit* or disease* or infection* or population* or human* or people* or group*) NEAR/2 contagio*)) OR TS=("skin to skin") OR TS=("mouth to mouth") OR TS=("mouth to skin") OR TS=("hand to mouth") OR TS=("face to face") OR TS=(touch*) OR TS=((horizontal* NEAR/1 transmit*)) OR TS=((respiratory NEAR/2 transmi*)) OR TS=(aerosol*) OR TS=(airborne) OR TS=("air borne") OR TS=(droplet*) OR TS=("air* particle*") OR TS=("respiratory particle*") OR TS=("expiratory particle*") OR TS=(exhal*) OR TS=(inhal*) OR TS=("air sampl*") OR TS=((respiratory NEAR/0 (route* or mode* or path* or method* or transmi* or spread*))) OR TS=((expiratory NEAR/0 (route* or mode* or path* or method* or transmi* or spread*))) OR TS=((airway* NEAR/0 (route* or mode* or path* or method* or transmi* or spread*))) OR TS=((air way* NEAR/0 (route* or mode* or path* or method* or transmi* or spread*))) OR TS=((breath* NEAR/0 (route* or mode* or path* or method* or transmi* or spread*))) OR TS=((("air flow*" or airflow* or aerodynamic* or "air condition*" or cough* or sneez* or breath* or sing or singing or shout* or (air NEAR/1 circulat*) or (air NEAR/1 recirculation) or (air NEAR/1 re-circulation)) and (transmission* or transmit* or distanc* or dispers*))) OR TS=((ventilation or ventilated) and (transmission* or distanc* or dispers*)) OR TS=(bioaerosol*) OR TS=((fomite* or fomes)) OR TS=((contaminat* or transmi*)

NEAR/2 (surface* or environment* or touch* or object* or equipment or food or drink*)) OR TS=((Virus or viral*) NEAR/4 (touch* or surface*)) OR TS=((bacteri* NEAR/4 (touch* or surface*)) OR TS=((body or bodily) NEAR/0 fluid*)) OR TS=((body or bodily) NEAR/0 secretion*)) OR TS=(saliva*) OR TS=(spit*) OR TS=((muc\$us or mucosa)) OR TS=((phlegm or sputum)) OR TS=((nostril* or nasal) NEAR/2 (discharge* or secretion*)) OR TS=((kiss or kissing)) OR TS=((mouth or tongue or lip*) NEAR/2 contact*)) OR TS=((shared or sharing) NEAR/2 (utensil* or fork* or spoon* or knife or knives or cup* or mug* or glass* or tumbler* or food or drink*)) OR TS=(sexual* NEAR/3 (transmi* or spread* or contact* or disease* or infect*)) OR TS=(Vagina* NEAR/3 (fluid* or secret* or discharge* or transmi* or spread* or disease* or contact*)) OR TS=((penile or penis) NEAR/3 (fluid* or secret* or discharge* or ejaculat* or transmi* or spread* or disease* or contact*)) OR TS=(ejaculat* NEAR/3 fluid*) OR TS=(“seminal fluid”) OR TS=(semen)

39 results

Annexe B. Study selection flowchart

Figure B.1. PRISMA diagram



Text version of Figure B.1. PRISMA diagram

A PRISMA diagram showing the flow of studies through this systematic evidence summary, ultimately including 3 studies.

From identification of studies via databases and registers, n=6,399 records identified from databases:

- Ovid Medline (n=3,053)
- Ovid Embase (n=3,307)
- Web of Science Preprint Citation Index (n=39)

From these, records removed before screening:

- duplicate records removed using Deduplick (n=2,047)
- records removed for other reasons (n=0)

n=4,352 records screened, of which n=4,213 were excluded, leaving n=139 papers sought for retrieval, of which n=1 was not retrieved.

No studies were identified from identification of studies via other methods.

Of the n=138 papers assessed for eligibility, n=135 reports were excluded:

- no relevant outcomes (n=112)
- not English language (n=6)
- wrong exposure (n=7)
- wrong study type (n=8)
- wrong publication type (n=2)

n=3 papers included in the systematic evidence summary.

Annexe C. Excluded full texts

No relevant outcomes (112 studies)

Abad R and others. '[Outbreak of invasive meningococcal disease caused by a meningococcus serogroup B expressing a rare porA genosubtype \(19-54, 15\), Spain, March to April 2024](#)' Euro Surveillance: Bulletin Européen sur les Maladies Transmissibles = European Communicable Disease Bulletin 2025: volume 30, issue 44

Acheson P and others. '[A cluster of four cases of meningococcal disease in a single nuclear family](#)' Archives of Disease in Childhood 2012: volume 97, issue 3, pages 248 to 249

Aguilera J-F and others. '[Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000](#)' Emerging Infectious Diseases 2002: volume 8, issue 8, pages 761 to 767

Andersen J and others. '[Surveillance of cases of meningococcal disease associated with military recruits studied for meningococcal carriage](#)' Scandinavian Journal of Infectious Diseases 2000: volume 32, issue 5, pages 527 to 531

Anonymous. '[Household transmission of Neisseria meningitidis in the African meningitis belt: a longitudinal cohort study](#)' The Lancet Global Health 2016: volume 4, issue 12, pages e989 to e995

Anonymous. '[Meningococcal disease associated with the Hajj--update](#)' Communicable Disease Report CDR Weekly 2000: volume 10, issue 19, pages 169

Anonymous. '[Serogroup W-135 meningococcal disease among travelers returning from Saudi Arabia--United States, 2000](#)' MMWR - Morbidity and Mortality Weekly Report 2000: volume 49, issue 16, pages 345 to 346

Anonymous. '[Update: assessment of risk for meningococcal disease associated with the Hajj 2001](#)' MMWR - Morbidity and Mortality Weekly Report 2001: volume 50, issue 12, pages 221 to 222

Anonymous. '[Risk for meningococcal disease associated with the Hajj 2001](#)' MMWR - Morbidity and Mortality Weekly Report 2001: volume 50, issue 6, pages 97 to 98

Anonymous. '[Laboratory-acquired meningococcal disease--United States, 2000](#)' MMWR - Morbidity and Mortality Weekly Report 2002: volume 51, issue 7, pages 141 to 144

Anonymous. '[Emergence of fluoroquinolone-resistant Neisseria meningitidis--Minnesota and North Dakota, 2007-2008](#)' MMWR - Morbidity and Mortality Weekly Report 2008: volume 57, issue 7, pages 173 to 175

Anonymous. '[Notes from the field: serogroup C invasive meningococcal disease among men who have sex with men - New York City, 2010-2012](#)' MMWR - Morbidity and Mortality Weekly Report 2013: volume 61, issue 51, page 1,048

Arnold FW and others. '[Meningococcal carriage and transmission dynamics in college students in Louisville, Kentucky](#)' PLOS ONE [Electronic Resource] 2026: volume 21, issue 3, article e0344194

Aubert L and others. '[Serogroup C invasive meningococcal disease among men who have sex with men and in gay-oriented social venues in the Paris region: July 2013 to December 2014](#)' Euro Surveillance: Bulletin Européen sur les Maladies Transmissibles = European Communicable Disease Bulletin 2015: volume 20, issue 3

Bazan JA and others. '[Large Cluster of *Neisseria meningitidis* Urethritis in Columbus, Ohio, 2015](#)' Clinical Infectious Diseases 2017: volume 65, issue 1, pages 92 to 99

Berg S and others. '[Incidence, serogroups and case-fatality rate of invasive meningococcal infections in a Swedish region 1975-1989](#)' Scandinavian Journal of Infectious Diseases 1992: volume 24, issue 3, page 333 to 338

Bharti N and others. '[Spatial dynamics of meningococcal meningitis in Niger: observed patterns in comparison with measles](#)' Epidemiology and Infection 2012: volume 140, issue 8, pages 1,356 to 1,365

Biswas HH and others. '[Notes from the Field: Outbreak of Serogroup B Meningococcal Disease at a University - California, 2016](#)' MMWR - Morbidity and Mortality Weekly Report 2016: volume 65, issue 20, pages 520 to 521

Broome CV and others. '[Epidemic group C meningococcal meningitis in Upper Volta, 1979](#)' Bulletin of the World Health Organization 1983: volume 61, issue 2, pages 325 to 330

Brown JW and others. '[Meningococcal Infections—Fort Ord and California](#)' California Medicine 1965: volume 102, pages 171 to 180

Cardenosa N and others. '[Carriers of *Neisseria meningitidis* in household contacts of meningococcal disease cases in Catalonia \(Spain\)](#)' European Journal of Epidemiology 2001: volume 17, issue 9, pages 877 to 884

Cartwright KA and others. '[Meningococcal carriage in close contacts of cases](#)' Epidemiology and Infection 1991: volume 106, issue 1, pages 133 to 141

Caugant DA and others. '[Transmission of *Neisseria meningitidis* among asymptomatic military recruits and antibody analysis](#)' Epidemiology and Infection 1992: volume 109, issue 2, pages 241 to 253

Ceyhan M and others. '[Acquisition of meningococcal serogroup W-135 carriage in Turkish Hajj pilgrims who had received the quadrivalent meningococcal polysaccharide vaccine](#)' Clinical and Vaccine Immunology: CVI 2013: volume 20, issue 1, pages 66 to 68

Ceyhan M and others. '[Bacterial agents causing meningitis during 2013-2014 in Turkey: A multi-center hospital-based prospective surveillance study](#)' Human vaccines and Immunotherapeutics 2016: volume 12, issue 11, pages 2,940 to 2,945

Chacon-Cruz E and others. '[An outbreak of serogroup C \(ST-11\) meningococcal disease in Tijuana, Mexico](#)' Therapeutic Advances in Vaccines 2014: volume 2, issue 3, pages 71 to 76

Cochi SL and others. '[Control of epidemic group A meningococcal meningitis in Nepal](#)' International Journal of Epidemiology 1987: volume 16, issue 1, pages 91 to 97

Cooke RP and others. '[Secondary cases of meningococcal infection among close family and household contacts in England and Wales, 1984-7](#)' BMJ 1989: volume 298, issue 6,673, pages 555 to 558

Davies AL and others. '[Risk factors for *Neisseria meningitidis* carriage in a school during a community outbreak of meningococcal infection](#)' Epidemiology and Infection 1996: volume 117, issue 2, pages 259 to 266

Davis LC and others. '[Meningococcal disease in a backpackers hostel in Scotland: a risk assessment for prophylaxis](#)' Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin 2009: volume 14, issue 31

Doyle TJ and others. '[Concurrent Outbreaks of Hepatitis A, Invasive Meningococcal Disease, and Mpox, Florida, USA, 2021-2022](#)' Emerging Infectious Diseases 2024: volume 30, issue 4

Elias J and others. '[Evidence for indirect nosocomial transmission of *Neisseria meningitidis* resulting in two cases of invasive meningococcal disease](#)' Journal of Clinical Microbiology 2006: volume 44, issue 11, pages 4,276 to 4,278

Farries JS and others. '[Meningococcal infections in Bolton, 1971-74](#)' Lancet 1975: volume 2, issue 7925, pages 118 to 120

Fawcett S and others. '[Meningococcal infections in the Hamilton area during 1978](#)' Canadian Medical Association Journal 1980: volume 122, issue 5, pages 541 to 545

Feigin RD and others. '[Epidemic meningococcal disease in an elementary-school classroom](#)' New England Journal of Medicine 1982: volume 307, issue 20, pages 1,255 to 1,257

Hao L and others. '[Distinct evolutionary patterns of *Neisseria meningitidis* serogroup B disease outbreaks at two universities in the USA](#)' Microbial Genomics 2018: volume 4, issue 4, pages 1 to 10

Hassan-King M and others. '[An epidemic of meningococcal infection at Zaria, Northern Nigeria. 3. Meningococcal carriage](#)' Transactions of the Royal Society of Tropical Medicine and Hygiene 1979: volume 73, issue 5, pages 567 to 573

Hodgson A and others. '[Risk factors for meningococcal meningitis in northern Ghana](#)' Transactions of the Royal Society of Tropical Medicine and Hygiene 2001: volume 95, issue 5, pages 477 to 480

Hudson PJ and others. '[Evidence for school transmission of *Neisseria meningitidis* during a Vermont outbreak](#)' Pediatric Infectious Disease 1986: volume 5, issue 2, pages 213 to 217

Ibarz-Pavon AB and others. '[Epidemiology, molecular characterization and antibiotic resistance of *Neisseria meningitidis* from patients ≤15 years in Manhica, rural Mozambique](#)' PLOS ONE [Electronic Resource] 2011: volume 6, issue 6, article e19717

Imrey PB and others. '[Meningococcal carriage, alcohol consumption, and campus bar patronage in a serogroup C meningococcal disease outbreak](#)' Journal of Clinical Microbiology 1995: volume 33, issue 12, pages 3,133 to 3,137

Imrey PB and others. '[Outbreak of serogroup C meningococcal disease associated with campus bar patronage](#)' American Journal of Epidemiology 1996: volume 143, issue 6, pages 624 to 630

Irwin DJ and others. '[Carriage of *Neisseria meningitidis* in residents and staff at a residential home for elderly people following a case of invasive disease](#)' Communicable Disease and Public Health 2000: volume 3, issue 3, pages 172 to 174

Iser BPM and others. '[Outbreak of *Neisseria meningitidis* C in workers at a large food-processing plant in Brazil: challenges of controlling disease spread to the larger community](#)' Epidemiology and Infection 2012: volume 140, issue 5, pages 906 to 915

Jacobson JA and others. '[The risk of meningitis among classroom contacts during an epidemic of meningococcal disease](#)' American Journal of Epidemiology 1976: volume 104, issue 5, pages 552 to 555

Jacquinet S and others. '[Outbreak of invasive meningococcal disease caused by a meningococcus serogroup B in a nursery school, Wallonia, Belgium, 2018](#)' Euro Surveillance: Bulletin Européen sur les Maladies Transmissibles = European Communicable Disease Bulletin 2022: volume 27, issue 9

Jo YM and others. '[Cluster of serogroup W-135 meningococcal disease in 3 military recruits](#)' Journal of Korean Medical Science 2015: volume 30, issue 5, pages 662 to 665

Juscamayta-Lopez E and others. '[Emergence of ciprofloxacin-resistant *Neisseria meningitidis* B from asymptomatic carriers during an outbreak in Peru, 2017](#)' Journal of Medical Microbiology 2021: volume 70, issue 1

Kamiya H and others. '[Meningococcal disease among men who have sex with men - United States, January 2012-June 2015](#)' MMWR - Morbidity and Mortality Weekly Report 2015: volume 64, issue 44, pages 1,256 to 1,257

Kanai M and others. '[Meningococcal disease outbreak related to the World Scout Jamboree in Japan, 2015](#)' Western Pacific Surveillance Response Journal 2017: volume 8, issue 2, pages 25 to 30

Korzeniewski K and others. '[Evaluation of *Neisseria meningitidis* Carriage with the Analysis of Serogroups, Genogroups and Clonal Complexes among Polish Soldiers](#)' Polish Journal of Microbiology/Polskie Towarzystwo Mikrobiologow/The Polish Society of Microbiologists 2018: volume 67, issue 4, pages 493 to 500

Kratz MM and others. '[Community-Based Outbreak of *Neisseria meningitidis* Serogroup C Infection in Men who Have Sex with Men, New York City, New York, USA, 2010-2013](#)' Emerging Infectious Diseases 2015: volume 21, issue 8, pages 1,379 to 1,386

Krause G and others. '[Marijuana use and social networks in a community outbreak of meningococcal disease](#)' Southern Medical Journal 2001: volume 94, issue 5, pages 482 to 485

Kremastinou J and others. '[Carriage of *Neisseria meningitidis* and *Neisseria lactamica* in northern Greece](#)' FEMS Immunology & Medical Microbiology 2003: volume 39, issue 1, pages 23 to 29

Kristiansen BE and others. '[Which contacts of patients with meningococcal disease carry the pathogenic strain of *Neisseria meningitidis*? A population based study](#)' BMJ 1998: volume 317, issue 7159, pages 621 to 625

Kristiansen BE and others. '[Preventing secondary cases of meningococcal disease by identifying and eradicating disease-causing strains in close contacts of patients](#)' Scandinavian Journal of Infectious Diseases 1992: volume 24, issue 2, pages 165 to 173

Lahra MM and others. '[Investigation and response to an outbreak of *Neisseria meningitidis* serogroup Y ST-1466 urogenital infections, Australia](#)' Communicable Diseases Intelligence 2024: volume 48

Lemos APSd and others. '[Emergence of *Neisseria meningitidis* W South American sublineage strain variant in Brazil: disease and carriage](#)' Journal of Medical Microbiology 2022: volume 71, issue 2

Lingappa JR and others. '[Serogroup W-135 meningococcal disease during the Hajj, 2000](#)' Emerging Infectious Diseases 2003: volume 9, issue 6, pages 665 to 671

Liphaus BL and others. '[Outbreak of *Neisseria meningitidis* C in a Brazilian oil refinery involving an adjacent community](#)' Enfermedades Infecciosas y Microbiologia Clinica 2013: volume 31, issue 2, pages 88 to 92

Lucidarme J and others. '[Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage](#)' Journal of Infection 2015: volume 71, issue 5, pages 544 to 552

MacLennan JM and others. '[Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey results](#)' The Lancet Infectious Diseases 2021: volume 21, issue 5, pages 677 to 687

Mandal S and others. '[Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States](#)' Clinical Infectious Diseases 2013: volume 57, issue 3, pages 344 to 348

Mayoral Cortes JM and others. '[Community cluster of meningococcal disease by *Neisseria meningitidis* serogroup C in Andalusia, Spain, March to May 2011](#)' Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin 2012: volume 17, issue 36, 20261

McMahan DA and others. '[Notes from the Field: Expanded Chemoprophylaxis Offered in Response to a Case of Meningococcal Meningitis in an Elementary School - Indiana, 2015](#)' MMWR - Morbidity and Mortality Weekly Report 2016: volume 65, issue 20, page 522

McMillan M and others. '[B Part of It study: a longitudinal study to assess carriage of *Neisseria meningitidis* in first year university students in South Australia](#)' Human vaccines and Immunotherapeutics 2019: volume 15, issue 4, pages 987 to 994

McNamara LA and others. '[First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak](#)' Pediatrics 2015: volume 135, issue 5, pages 798 to 804

Meiring S and others. '[Human Immunodeficiency Virus Infection Is Associated With Increased Meningococcal Carriage Acquisition Among First-year Students in 2 South African Universities](#)' Clinical Infectious Diseases 2021: volume 73, issue 1, pages e28 to e38

Menichetti F and others. '[Invasive Meningococcal Disease due to group C *N. meningitidis* ST11 \(cc11\): The Tuscany cluster 2015-2016](#)' Vaccine 2018: volume 36, issue 40, pages 5,962 to 5,966

Miglietta A and others. '[Carriage rates and risk factors during an outbreak of invasive meningococcal disease due to *Neisseria meningitidis* serogroup C ST-11 \(cc11\) in Tuscany, Italy: a cross-sectional study](#)' BMC Infectious Diseases 2019: volume 19, issue 1, page 29

Miglietta A and others. '[Interconnected clusters of invasive meningococcal disease due to *Neisseria meningitidis* serogroup C ST-11 \(cc11\), involving bisexuals and men who have sex with men, with discos and gay-venues hotspots of transmission, Tuscany, Italy, 2015 to 2016](#)' Euro Surveillance: Bulletin Européen sur les Maladies Transmissibles = European Communicable Disease Bulletin 2018: volume 23, issue 34

Mulhall RM and others. '[Resolution of a Protracted Serogroup B Meningococcal Outbreak with Whole-Genome Sequencing Shows Interspecies Genetic Transfer](#)' Journal of Clinical Microbiology 2016: volume 54, issue 12, pages 2,891 to 2,899

Mustapha MM and others. '[Transmission Dynamics and Microevolution of *Neisseria meningitidis* During Carriage and Invasive Disease in High School Students in Georgia and Maryland, 2006-2007](#)' Journal of Infectious Diseases 2021: volume 223, issue 12, pages 2,038 to 2,047

Nanduri S and others. '[Outbreak of Serogroup C Meningococcal Disease Primarily Affecting Men Who Have Sex with Men - Southern California, 2016](#)' MMWR - Morbidity and Mortality Weekly Report 2016: volume 65, issue 35, pages 939 to 940

Nunes AMPB and others. '[Meningococcal Carriage among Adolescents after Mass Meningococcal C Conjugate Vaccination Campaigns in Salvador, Brazil](#)' PLOS ONE [Electronic Resource] 2016: volume 11, issue 11, article e0166475

O'Connor L and others. '[A prolonged outbreak of invasive meningococcal disease in an extended Irish Traveller family across three Health Service Executive \(HSE\) areas in Ireland, 2010 to 2013](#)' Euro Surveillance: Bulletin Européen sur les Maladies Transmissibles = European Communicable Disease Bulletin 2015: volume 20, issue 21

Patel MS and others. '[Epidemic meningococcal meningitis in central Australia, 1987-1991](#)' Medical Journal of Australia 1993: volume 158, issue 5, pages 336 to 340

Perez-Gonzalez A and others. '[Meningococcal carriage in men who have sex with men presenting at a sexual health unit in Spain](#)' European Journal of Clinical Microbiology and Infectious Diseases 2023: volume 42, issue 3, pages 287 to 296

Puleston R and others. '[An unusual transmission event of *Neisseria meningitidis* serogroup W135 type 2a in a healthcare setting, England, 2012](#)' Euro Surveillance: Bulletin Européen sur

les Maladies Transmissibles = European Communicable Disease Bulletin 2012: volume 17, issue 44

Putsch RW and others. '[Neisseria meningitidis, a respiratory pathogen?](#)' Journal of Infectious Diseases 1970: volume 121, issue 1, pages 48 to 54

Razzaq N and others. '[A possible secondary case of pneumococcal meningitis](#)' Journal of Infection 1998: volume 37, issue 3, pages 290 to 291

Ridpath A and others. '[Risk Factors for Serogroup C Meningococcal Disease during Outbreak among Men who Have Sex with Men, New York City, New York, USA](#)' Emerging Infectious Diseases 2015: volume 21, issue 8, pages 1,458 to 1,461

Robinson M and others. '[Statewide Outbreak of Neisseria meningitidis Serogroup Y, Sequence Type 1466 - Virginia, 2022-2024](#)' MMWR - Morbidity and Mortality Weekly Report 2024: volume 73, issue 43, pages 973 to 977

Robinson P. '[Observations on an outbreak of meningitis](#)' Health Visitor 1988: volume 61, issue 2, pages 46 to 48

Robinson P and others. '[Risk-factors for meningococcal disease in Victoria, Australia, in 1997](#)' Epidemiology and Infection 2001: volume 127, issue 2, pages 261 to 268

Robinson P and others. '[An outbreak of serogroup C meningococcal disease associated with a secondary school](#)' Communicable Diseases Intelligence Quarterly Report 2001: volume 25, issue 3, pages 121 to 125

Round A and others. '[Public health management of an outbreak of group C meningococcal disease in university campus residents](#)' European Journal of Public Health 2001: volume 11, issue 4, pages 431 to 436

Rude JM and others. '[Rapid response to meningococcal disease cluster in Foya district, Lofa County, Liberia January to February 2018](#)' The Pan African medical journal 2019: volume 33, page 6

Samuelsson S and others. '[Prevention of secondary cases of meningococcal disease in Denmark](#)' Epidemiology and Infection 2000: volume 124, issue 3, pages 433 to 440

Sejvar JJ and others. '[Assessing the risk of laboratory-acquired meningococcal disease](#)' Journal of Clinical Microbiology 2005: volume 43, issue 9, pages 4,811 to 4,814

Simmons G and others. '[Carriage of Neisseria meningitidis among household contacts of patients with meningococcal disease in New Zealand](#)' European Journal of Clinical Microbiology and Infectious Diseases 2001: volume 20, issue 4, pages 237 to 242

Smilovic V and others. '[Familial epidemic of meningococcal disease](#)' Croatian Medical Journal 1998: volume 39, issue 1, pages 62 to 65

Smith-Palmer A and others. '[Outbreak of *Neisseria meningitidis* capsular group W among scouts returning from the World Scout Jamboree, Japan, 2015](#)' Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin 2016: volume 21, issue 45

Stefanelli P and others. '[Cluster of invasive *Neisseria meningitidis* infections on a cruise ship, Italy, October 2012](#)' Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin 2012: volume 17, issue 50

Stuart JM and others. '[An outbreak of meningococcal disease in Stonehouse: planning and execution of a large-scale survey](#)' Epidemiology and Infection 1987: volume 99, issue 3, pages 579 to 589

Sudbury EL and others. '[Case manifestations and public health response for outbreak of meningococcal W disease, central Australia, 2017](#)' Emerging Infectious Diseases 2020: volume 26, issue 7, pages 1,355 to 1,363

Tappero JW and others. '[Meningococcal disease in Los Angeles County, California, and among men in the county jails](#)' New England Journal of Medicine 1996: volume 335, issue 12, pages 833 to 840

Tefera Z and others. '[Carriage rate of *Neisseria meningitidis*, antibiotic susceptibility pattern and associated risk factors among primary school children in Gondar town, Northwest Ethiopia](#)' BMC Infectious Diseases 2020: volume 20, issue 1, page 358

Tekin RT and others. '[The prevalence, serogroup distribution and risk factors of meningococcal carriage in adolescents and young adults in Turkey](#)' Human Vaccines and Immunotherapeutics 2017: volume 13, issue 5, pages 1,182 to 1,189

Thabuis A and others. '[Community outbreak of serogroup B invasive meningococcal disease in Beaujolais, France, February to June 2016: from alert to targeted vaccination](#)' Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin 2018: volume 23, issue 28

Tinggaard M and others. '[Oral and anal carriage of *Neisseria meningitidis* among sexually active HIV-infected men who have sex with men in Denmark 2014-15](#)' International Journal of Infectious Diseases 2021: volume 105, pages 337 to 344

Tsang RSW and others. '[Outbreak of serogroup C meningococcal disease caused by a variant of *Neisseria meningitidis* serotype 2a ET-15 in a community of men who have sex with men](#)' Journal of Clinical Microbiology 2003: volume 41, issue 9, pages 4,411 to 4,414

Tully J and others. '[Risk and protective factors for meningococcal disease in adolescents: matched cohort study](#)' BMJ 2006: volume 332, issue 7539, pages 445 to 450

Valinsky L and others. '[A cluster of invasive meningococcal disease revealed by the characterization of a novel serogroup B meningococcal clone](#)' Epidemiology and Infection 2016: volume 144, issue 1, pages 183 to 188

Wall R and others. '[Meningococcal infection: evidence for school transmission](#)' Journal of Infection 1991: volume 23, issue 2, pages 155 to 159

Wattle SV and others. '[Meningococcal carriage in Norwegian teenagers: strain characterisation and assessment of risk factors](#)' Epidemiology and Infection 2020: volume 148, page e80

Weiss D and others. '[Epidemiologic investigation and targeted vaccination initiative in response to an outbreak of meningococcal disease among illicit drug users in Brooklyn, New York](#)' Clinical Infectious Diseases 2009: volume 48, issue 7, pages 894 to 901

Wilder-Smith A. '[W135 meningococcal carriage in association with the Hajj pilgrimage 2001: the Singapore experience](#)' International Journal of Antimicrobial Agents 2003: volume 21, issue 2, pages 112 to 115

Wilder-Smith A and others. '[Acquisition of W135 meningococcal carriage in Hajj pilgrims and transmission to household contacts: prospective study](#)' BMJ 2002: volume 325, issue 7360, pages 365 to 366

Wilder-Smith A and others. '[Persistence of W135 *Neisseria meningitidis* carriage in returning Hajj pilgrims: risk for early and late transmission to household contacts](#)' Emerging Infectious Diseases 2003: volume 9, issue 1, pages 123 to 126

Zeng X and others. '[An Outbreak of Serogroup Y Meningococcal Meningitis in a Private Secondary Vocational School - Guangzhou City, Guangdong Province, China, 2023](#)' China CDC Weekly 2024: volume 6, issue 12, pages 242 to 246

Zhang J and others. '[Molecular characteristics of *Neisseria meningitidis* isolated during an outbreak in a jail: association with the spread and distribution of ST-4821 complex serogroup C clone in China](#)' Biomedical and Environmental Sciences 2013: volume 26, issue 5, pages 331 to 337

Not English language (6 studies)

Li J and others. '[\[Clinical characteristics and investigation for the first death case of group Y epidemic cerebrospinal meningitis in Henan Province, 2024\]](#)' Chung-Hua Yu Fang i Hsueh Tsa Chih [Chinese Journal of Preventive Medicine] 2026: volume 60, issue 2, pages 244 to 246

Matsika-Claquin MD and others. '[Meningococcal W135 infection epidemics associated with pilgrimage to Mecca in 2000](#)' *Epidemie d'infections a meningocoque W135 liee au pelerinage de la Mecque de 2000*. 2001: volume 30, issue 31, pages 1,529 to 1,534

Matsika-Claquin MD and others. '[Neisseria meningitidis serogroup W135 epidemic related to the 2000 Haj, France](#)' *Presse Medicale* 2001: volume 30, issue 31, pages 1,529 to 1,534

Mbelesso P and others. '[Bacterial meningitis in adult patients in Central African hospitals](#)' *Les meningites bacteriennes de l'adulte en milieu hospitalier centrafricain*. 2006: volume 99, issue 4, pages 261 to 263

Ohtaki M and others. '[Bronchopneumonia caused by Neisseria meningitidis--probable transmission by a family member who had been in Hong Kong](#)' *Nihon Kyobu Shikkan Gakkai Zasshi. Japanese Journal of Thoracic Diseases* 1997: volume 35, issue 4, pages 461 to 465

Sahiner N and others. '[Investigation of neisseria meningitidis carriage and its risk factors following a cluster of meningococcal disease in diyarbakir](#)' *Nobel Medicus* 2011: volume 7, issue 3, pages 28 to 35

Wrong exposure (7 studies)

Anonymous. '[Bacterial meningitis after intrapartum spinal anesthesia - New York and Ohio, 2008-2009](#)' *MMWR - Morbidity and Mortality Weekly Report* 2010: volume 59, issue 3, pages 65 to 69

Chitnis AS and others. '[Outbreak of bacterial meningitis among patients undergoing myelography at an outpatient radiology clinic](#)' *Journal of the American College of Radiology* 2012: volume 9, issue 3, pages 185 to 190

Galea P and others. '[Tuberculous meningitis in children: a review of 15 cases](#)' *Scottish Medical Journal* 1988: volume 33, issue 1, pages 205 to 207

Leelarasamee A and others. '[Severe pneumococcal infection at a Thai hospital](#)' *International Journal of Infectious Diseases* 1999: volume 3, issue 3, pages 147 to 152

Rubin L and others. '[Meningitis following spinal anesthesia: 6 cases in 5 years](#)' *Infection Control and Hospital Epidemiology* 2007: volume 28, issue 10, pages 1,187 to 1,190

Whiley DM and others. '[Azithromycin-resistant Neisseria gonorrhoeae spreading amongst men who have sex with men \(MSM\) and heterosexuals in New South Wales, Australia, 2017](#)' *Journal of Antimicrobial Chemotherapy* 2018: volume 73, issue 5, pages 1,242 to 1,246

Wong A and others. '[Welders are at increased risk for invasive pneumococcal disease](#)' International Journal of Infectious Diseases 2010: volume 14, issue 9, pages e796 to e799

Wrong study type (8 studies)

Coudeville L and others. '[Disease transmission and mass gatherings: a case study on meningococcal infection during Hajj](#)' BMC Infectious Diseases 2022: volume 22, issue 1, page 275

Cummiskey J and others. '[Report of a serious reportable communicable disease at a major sporting event](#)' Journal of Sports Medicine and Physical Fitness 2008: volume 48, issue 2, pages 125 to 128

Holmes JC and others. '[Rapid Transmission of a Hyper-Virulent Meningococcal Clone Due to High Effective Contact Numbers and Super Spreaders](#)' Frontiers in Genetics 2020: volume 11, 579411

Marshall HS and others. '[Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia](#)' New England Journal of Medicine 2020: volume 382, issue 4, pages 318 to 327

Muttalif AR and others. '[Incidence and Prevention of Invasive Meningococcal Disease in Global Mass Gathering Events](#)' Infectious Diseases and Therapy 2019: volume 8, issue 4, pages 569 to 579

Parikh SR and others. '[Primary meningococcal conjunctivitis: Summary of evidence for the clinical and public health management of cases and close contacts](#)' Journal of Infection 2019: volume 79, issue 6, pages 490 to 494

Petsas A and others. '[A secondary case of meningococcal disease in an ambulance worker, Berkshire, November 2007](#)' Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin 2008: volume 13, issue 4

Simon MS and others. '[Invasive meningococcal disease in men who have sex with men](#)' Annals of Internal Medicine 2013: volume 159, issue 4, pages 300 to 301

Wrong publication type (2 studies)

Herman J and others. '[Long-interval transmission of meningococcal disease](#)' Journal of Infectious Diseases 1980: volume 142, issue 6, page 945

Reintjes R and others. '[Carriage of meningococci in contacts of patients with meningococcal disease. Age and other risk factors need to be taken into account](#)' BMJ (Clinical research ed.) 1999: volume 318, issue 7184, pages 665 to 666

Annexe D. Data extraction tables

Table D.1. Summary of studies identified on meningococcal disease serogroup B

Abbreviations: STI: sexually transmitted infections

Author, Year, Study Type	Country, time period	Serogroup / serotype	Population	Outcomes
Mitchell and others, 2008 (1) Case series	New Zealand, February to March 2007	B (B15P1.7,16)	Five people: Case 1: 20-year-old woman, ethnicity not reported, heterosexual. Presenting with symptomatic genital infection. Case 2: 23 year old man, ethnicity not reported, heterosexual, confirmed diagnosis of hepatitis B. Asymptomatic. Cases 3 to 5: 21 to 28 years, 66.6% men (n=2), ethnicity not reported, heterosexual. Asymptomatic.	Case 1 presented at a sexual health clinic with intermenstrual and post-coital bleeding. Pharyngeal, vaginal, cervical and urethral swabs were all positive for <i>N. meningitidis</i> (and negative for all other STI). Case 2 was the regular sexual partner of case 1 for approximately one year, reporting unprotected vaginal and oral sex. A pharyngeal swab from case 2 was subsequently positive for <i>N. meningitidis</i> . Both were treated with ciprofloxacin, and a pharyngeal swab taken from case 2 four days later was negative. Cases 3 to 5 were serogroups other than serogroup B. No transmission route confirmed for any of these cases.

Table D.2. Summary of studies identified on meningococcal serogroup C

Author, Year, Study Type	Country, time period	Meningococcal Serogroup / serotype	Population	Outcomes
Materna and others, 2010 (3) Outbreak report	USA, December 2009	Meningococcal serogroup C, ST-11 clonal complex	Three people: Index case: 36 year old man, ethnicity not reported, sexual orientation not reported. Case 1: 30 year old man, ethnicity not reported, sexual orientation not reported. Case 2: 47 year old man, ethnicity not reported, sexual orientation not reported.	The index case was found unconscious with a partially obstructed airway, with vomit and faeces on his body and clothing. As part of his treatment, his airway was suctioned, and an endotracheal tube was placed. Case 1 presented at his primary care physician 2 days after the index patient was found unconscious. After hospitalisation, blood and cerebrospinal fluid were positive for N. meningitidis. He was a police officer who assisted the index patient at the scene, adjusting the patient's body and head to assist with breathing. He then left the room. While handling the patient, he reported hearing hacking and gurgling but reported no droplets on his skin nor contact with respiratory

Author, Year, Study Type	Country, time period	Meningococcal Serogroup / serotype	Population	Outcomes
				secretions. He did not wear a mask, but did wear gloves. Case 2 began experiencing symptoms 5 days after coming into contact with the index case. After hospitalisation, blood and cerebrospinal fluid were positive for N. meningitidis. He was a respiratory therapist who assisted with the suction of the airway and endotracheal tube placement of the index case. He did not wear a mask, but did wear gloves. The authors suggest that in both secondary cases, unprotected exposure to infectious respiratory secretions (author defined as respiratory aerosols or secretions) may have resulted in transmission.

Table D.3. Summary of studies identified on meningococcal disease where meningococcal serogroup could not be determined

Author, Year, Study Type	Country, time period	Serogroup / serotype	Population	Outcomes
Talbot and others, 1981 (2) Case series	UK, not reported	Could not be determined (ungroupable in laboratory tests)	Three people: 26 year old man, Caucasian, sexual orientation not reported, presented with urethral discharge and dysuria. Age not reported, woman, ethnicity and sexual orientation not reported. Age not reported, woman, ethnicity and sexual orientation not reported.	A man presented with urethral discharge and dysuria, and a urethral swab was taken. Subsequently, cases 1 and 2, who were women, sexual partners of the man and both had pharyngeal, urethral, cervical and rectal swabs taken: - man: urethral swab positive - case 1: pharyngeal swab positive - case 2: cervical swab positive The authors suggest that the man acquired meningococcal disease from sexual contact with case 1 via oral-genital exposure and then he transmitted to case 2 via sexual transmission. Case 1 and 2 remained asymptomatic.

About the UK Health Security Agency

UK Health Security Agency (UKHSA) prevents, prepares for and responds to infectious diseases and environmental, radiological and chemical hazards, to keep all our communities safe, save lives and protect livelihoods. We provide scientific and operational leadership, working with local, national and international partners to protect the public's health.

[UKHSA](#) is an executive agency, sponsored by the [Department of Health and Social Care](#).

© Crown copyright 2026

Prepared by Tamsyn Harris, Lily Gabriel, Jennifer Hill, Aina Madathinal Shaju, Georgia Towson, Jodie Walker, and Serena Carville.

For queries relating to this document, contact: enquiries@ukhsa.gov.uk

Completed: 2 April 2026

Published: August 2026

Publication reference: GOV-20890 (PHR045b)

Suggested citation: names. Harris, T, Gabriel, L, Hill, J, Shaju, AM, Towson, G, Walker, J, and Carville, S. 'Routes of transmission of meningococcal infection; a systematic evidence summary'. UKHSA 2025



You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit [OGL](#). Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.



UKHSA supports the UN
Sustainable Development Goals

